Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial

INTRODUCTION: Pateclizumab (MLTA3698A) is a humanized mAb against lymphotoxin α (LTα), a transiently expressed cytokine on activated B and T cells (Th1, Th17), which are implicated in rheumatoid arthritis (RA) pathogenesis. This study was conducted to assess the safety, tolerability, < NOTE: For...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Emu, Brinda, Luca, Diana, Offutt, Carolyn, Grogan, Jane L, Rojkovich, Bernadette, Williams, Marna B, Tang, Meina T, Xiao, Jim, Lee, June H, Davis, John C
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: BioMed Central 2012
विषय:
Research Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC3392792/
https://ncbi.nlm.nih.gov/pubmed/22225620
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/ar3554
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन